Pharmacogenetics (DNA)

The field of Pharmacogenetics aids physicians in providing more personalized medicine for their patients. Knowing a patient’s metabolic status through SNP (single nucleotide polymorphism) genotyping provides insight and guidance for a physician when determining the appropriateness and efficacy of a patient’s drug regimen.

Cytochrome P450 liver enzymes including CYP2D6, and CYP2C19, as well as CYP3A4 and CYP3A5, are involved in the metabolism of a large number of drugs including opioid analgesics, selective seratonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA). CYP2C9 and VKORC1 are primary players in warfarin metabolism. Understanding how a patient’s genetics influences drug response is useful in guiding medication choice and dosing for these drugs and many others, ultimately improving overall cost, time to effective treatment, and satisfaction.

The GARS (Genetic Addiction Risk Score) panel includes SNPs that have been implicated in opiate addiction. Having a risk score for an individual may be useful as supplemental information when monitoring a patient who is taking opioid analgesics. It should be noted that there may be many environmental and sociological indicators that play a role in opioid addiction when determining a patient’s drug regimen. The GARS panel provides an important tool in helping to determine the level of monitoring necessary for a patient taking opioid analgesics.

At ChemaTox we pride ourselves in delivering genetic test results in a timely fashion that you can trust. We use our proven Taqman real time PCR assays to determine genotypes to bring the power of Pharmacogenetic information to our clients as quickly and reliably as possible.

CYP Metabolic panel:

CYP2D6*1,*2,*3,*4,*5,*6,*8,*10,*14,*17,*34,*35,*39,*41
CYP2D6 Copy Number Variant
CYP2C9*1,*2,*3
VKORC1
CYP2C19*1,*2,*3,*17
CYP3A4*1,*22
CYP3A5*1,*3

GARS (Genetic Addiction Risk Score):

5HTR2A, ANKK1, COMT, DRD1, DRD2, DRD4, NCAM1 OPRK1, OPRD1, OPRM1, TTC12